KR880001288A - 경구투여 형태의 서방성 약제학적 조성물 - Google Patents

경구투여 형태의 서방성 약제학적 조성물 Download PDF

Info

Publication number
KR880001288A
KR880001288A KR1019870007296A KR870007296A KR880001288A KR 880001288 A KR880001288 A KR 880001288A KR 1019870007296 A KR1019870007296 A KR 1019870007296A KR 870007296 A KR870007296 A KR 870007296A KR 880001288 A KR880001288 A KR 880001288A
Authority
KR
South Korea
Prior art keywords
composition
cellulose
oral dosage
dosage form
core matrix
Prior art date
Application number
KR1019870007296A
Other languages
English (en)
Inventor
재클린 러브그로우브 클레어
죤 필립스 안토니
알렉산더 라울린스 데이비드
알렉산더 테인쉬 데이비드
Original Assignee
제임스 에프. 나우톤
머어크 샤프 앤드 도옴 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에프. 나우톤, 머어크 샤프 앤드 도옴 리미티드 filed Critical 제임스 에프. 나우톤
Publication of KR880001288A publication Critical patent/KR880001288A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Abstract

내용 없음

Description

경구투여 형태의 서방성 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. (1)적어도 20%의 유도된 셀룰로오즈계 겔화제, 내부에 균일하게 분산된 약제 및 임의로 약제학적으로 허용 가능한 부형제를 함유하는 코어 매트릭스 및 (2) 코어 매트릭스를 둘러싸는 피복층을 포함하며, 이때 상기 피복물은 서서히 용해하는, 침수성 유도된 셀룰로오즈계 종합체인 경구투여 형태의 서방성 약제학적 조성물.
  2. 제1항에 있어서, 코어 매트릭스가 완충제를 함유하는 경구투여 형태의 조성물.
  3. 제2항에 있어서, 완충제가 시트르산인 경구투여 형태의 조성물.
  4. 제1항 내지 3항중의 어느 하나에 있어서, 코어 매트릭스 겔화제가 하이드록시프로필메틸셀룰로오즈인 경구투여 형태의 조성물.
  5. 제4항에 있어서, 하이드록시프로필메틸실룰로오즈가 약 4,000센티포이즈의 점도를 갖는 경구투여 형태의 조성물.
  6. 제1항 내지 5항중의 어느 하나에 있어서, 피복층 내의 유도된 셀룰로오즈계 중합체가 침수성, 수불용성 막 형성제인 경구투여 형태의 조성물.
  7. 제6항에 있어서, 막 형성제가 에틸 셀룰로오즈인 경구투여 형태의 조성물.
  8. 제1항 내지 제7항중의 어느 하나에 있어서, 약제가(+)-트랜스-1a,2,3,4a,5,6-헥사하이드로-9-하이드록시-4-(1-프로필)-4H-나프트[1,2-b]-1,4-옥사진 염화수소인 경구투여 형태의 조성물.
  9. 임의로 약제학적으로 허용가능한 부형제와 함께 내부에 균일하게 분산된 활성성분을 갖는 유도된 셀룰로오즈계 겔화제를 적어도 20% 함유하는 매트릭스를 형성시키고, 서서히 용해하는 침수성 유도된 셀룰로오즈계 중합체를 포함하는 상기 매트릭스 상에 피복물을 형성 시킴을 포함하는, 활성성분을 함유하는 경구투여 형태의 서방성 약제학적 조성물의 제조방법.
  10. 제9항에 있어서, 코어 매트릭스가 완충제를 함유하는 방법.
  11. 제10항에 있어서, 완충제가 시트르산인 방법.
  12. 제1항 내지 11항중의 어느 하나에 있어서, 코어 매트릭스 겔화제가 하이드록시프로필메틸 셀룰로오즈인 방법.
  13. 제12항에 있어서, 하이드록시프로필메틸 셀룰로오즈가 약 4,000센티포이즈의 점도를 갖는 방법.
  14. 제1항 내지 제13항중의 어느 하나에 있어서, 피복층 내의 유도된 셀룰로오즈계 중합체가 침수성, 수불용성 막 형성제인 방법.
  15. 제14항에 있어서, 막 형성제가 에틸 셀룰로오즈인 방법.
  16. 제9항 내지 15항중의 어느 하나에 있어서, 약제가(+)-트랜스-1a,2,3,4a,5,6-헥사하이드로-9-하이드록시-4-(1-프로필)-4H-나프트[1,2-b]-1,4-옥사진 염화수소인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870007296A 1986-07-09 1987-07-08 경구투여 형태의 서방성 약제학적 조성물 KR880001288A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8616669 1986-07-09
GB868616669A GB8616669D0 (en) 1986-07-09 1986-07-09 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
KR880001288A true KR880001288A (ko) 1988-04-22

Family

ID=10600761

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870007296A KR880001288A (ko) 1986-07-09 1987-07-08 경구투여 형태의 서방성 약제학적 조성물

Country Status (17)

Country Link
US (1) US4919938A (ko)
EP (1) EP0253541B1 (ko)
JP (1) JP2528130B2 (ko)
KR (1) KR880001288A (ko)
AT (1) ATE67408T1 (ko)
AU (1) AU598280B2 (ko)
CA (1) CA1303502C (ko)
DE (1) DE3773070D1 (ko)
DK (1) DK352387A (ko)
ES (1) ES2038181T3 (ko)
GB (1) GB8616669D0 (ko)
GR (1) GR3002755T3 (ko)
IE (1) IE59786B1 (ko)
IL (1) IL83017A0 (ko)
NZ (1) NZ220875A (ko)
PT (1) PT85213B (ko)
ZA (1) ZA874960B (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786509A (en) * 1987-05-18 1988-11-22 Schering Corporation Dry sustained release theophylline oral formulation
EP0325086A3 (en) * 1987-11-23 1990-10-31 Jago Research Ag Novel methods for obtaining therapeutic systems with controlled release of the drug
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
FR2640876B1 (ko) * 1988-12-28 1993-09-24 Jouveinal Sa
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US4931286A (en) * 1989-04-19 1990-06-05 Aqualon Company High gloss cellulose tablet coating
US5175003A (en) * 1990-04-06 1992-12-29 Biosytes Usa, Inc. Dual mechanism controlled release system for drug dosage forms
US5576306A (en) * 1991-03-01 1996-11-19 Dow Chemical Company Pharmaceutical compositions and uses of water-soluble, high-viscosity grade cellulose ethers
US5721221A (en) * 1991-03-08 1998-02-24 Regents Of The University Of Minnesota Lowering blood cholesterol levels using water soluble cellulose ethers
KR100205276B1 (ko) * 1991-10-04 1999-07-01 가마쿠라 아키오 서방성 정제
WO1994015643A1 (en) * 1992-12-30 1994-07-21 Fmc Corporation Readily available konjac glucomannan sustained release excipient
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
WO1998027845A1 (en) * 1996-12-20 1998-07-02 Reckitt & Colman France Improvements in or relating to packaging
US6656502B1 (en) * 1997-03-14 2003-12-02 Toray Industries, Inc. Sustained-release prostaglandin I derivative preparation
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
US6090411A (en) * 1998-03-09 2000-07-18 Temple University Monolithic tablet for controlled drug release
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
WO2001080824A2 (en) * 2000-04-19 2001-11-01 Eurand America, Inc. Dual mechanism timed release dosage forms for low dose drugs
US7674480B2 (en) * 2000-06-23 2010-03-09 Teva Pharmaceutical Industries Ltd. Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
US6881420B2 (en) 2000-06-23 2005-04-19 Teva Pharmaceutical Industries Ltd. Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
ES2282492T3 (es) 2001-11-30 2007-10-16 Pfizer Products Inc. Composiciones farmaceuticas de liberacion controlada orales de 5,8,14-triazatetraciclo (10.3.1.0(2,11).0(4,9)-hexadeca-2(11)3,5,7,9-pentaeno.
WO2003055525A1 (fr) * 2001-12-25 2003-07-10 Takeda Chemical Industries, Ltd. Preparations contenant un acide
EP1485078B1 (en) * 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran for the treatment of irritable bowel syndrome
TW200306866A (en) * 2002-05-07 2003-12-01 Akzo Nobel Nv A method to improve surface properties of pharmaceutical tablets
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
BR0315731A (pt) * 2002-10-30 2005-09-06 Pharmacia Corp Comprimidos orais de liberação prolongada e métodos para fabricar e usar os mesmos
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US7387793B2 (en) 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
EP1811975A2 (en) * 2004-10-19 2007-08-01 The State of Oregon Acting by and Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
CN100548309C (zh) * 2004-11-24 2009-10-14 东北制药总厂 司他夫定缓释片剂
EP2412366A4 (en) * 2009-03-25 2013-08-07 Lintec Corp SOLID PREPARATION
CA2882713A1 (en) * 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468172A (en) * 1973-03-28 1977-03-23 Benzon As Alfred Oral drug preparations
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
JPS5659707A (en) * 1979-10-19 1981-05-23 Toyo Jozo Co Ltd Lasting antibiotic pharmaceutical and its preparation
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
US4420480A (en) * 1981-11-20 1983-12-13 Merck & Co., Inc. Hexahydronaphth[1,2-b]-1,4-oxazines
CA1204745A (en) * 1981-11-20 1986-05-20 Merck Co. Hexahydronaphth (1,2-b) -1,4 -oxazines
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
DK151608C (da) * 1982-08-13 1988-06-20 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat med kontrolleret afgivelse
US4505890A (en) 1983-06-30 1985-03-19 E. R. Squibb & Sons, Inc. Controlled release formulation and method
IE56459B1 (en) * 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
FR2556965B1 (fr) 1983-12-21 1986-08-22 Rhone Poulenc Sante Nouvelle forme galenique du ketoprofene a liberation controlee
HU193979B (en) * 1984-06-12 1987-12-28 Sandoz Ag Process for producing naphtoxazine derivatives and pharmaceutical compositions containing them
US4610870A (en) 1984-10-05 1986-09-09 E. R. Squibb & Sons, Inc. Controlled release formulation
AU592065B2 (en) * 1984-10-09 1990-01-04 Dow Chemical Company, The Sustained release dosage form based on highly plasticized cellulose ether gels
US4695591A (en) * 1985-03-29 1987-09-22 Schering Corporation Controlled release dosage forms comprising hydroxypropylmethylcellulose
US4693896A (en) * 1985-10-07 1987-09-15 Fmc Corporation Ethylcellulose-coated, gastric-disintegrable aspirin tablet
US4816264A (en) * 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
IT1213080B (it) * 1986-06-17 1989-12-07 Recordati Chem Pharm Sistemi terapeutico per la cessione controllata di farmaci.

Also Published As

Publication number Publication date
DK352387A (da) 1988-01-10
AU7534087A (en) 1988-01-14
PT85213B (pt) 1990-03-30
GR3002755T3 (en) 1993-01-25
AU598280B2 (en) 1990-06-21
JP2528130B2 (ja) 1996-08-28
ES2038181T3 (es) 1993-07-16
JPS6323814A (ja) 1988-02-01
IE59786B1 (en) 1994-04-06
DE3773070D1 (de) 1991-10-24
EP0253541B1 (en) 1991-09-18
NZ220875A (en) 1990-11-27
ATE67408T1 (de) 1991-10-15
PT85213A (en) 1987-07-01
EP0253541A3 (en) 1988-04-27
IE871830L (en) 1988-01-09
US4919938A (en) 1990-04-24
DK352387D0 (da) 1987-07-08
EP0253541A2 (en) 1988-01-20
CA1303502C (en) 1992-06-16
IL83017A0 (en) 1987-12-20
ZA874960B (en) 1988-08-31
GB8616669D0 (en) 1986-08-13

Similar Documents

Publication Publication Date Title
KR880001288A (ko) 경구투여 형태의 서방성 약제학적 조성물
US4309405A (en) Sustained release pharmaceutical compositions
KR950702409A (ko) 방출 조절 모르핀 제제(controlled release morphine preparation)
KR900700089A (ko) 전신성 피부 투과적 투여를 위한 약학적 조성물
KR840006765A (ko) 지속성 방출 고형 제형의 제조방법
ATE99927T1 (de) Pharmazeutische formulierungen.
KR850004392A (ko) 경구투여용 장기작용 약제의 제조방법 및 조성물
KR910011243A (ko) 서방성 약제 용량 단위
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
KR880000088A (ko) 지속적인 방출 제제
DE3773468D1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
KR870700344A (ko) 유효 화합물을 서서히 방출하는 신규 약제, 그의 제조방법 및 이신규 제제물의 용도
ATE310508T1 (de) Therapeutische formulierung enthaltende dosierungsform
RU94045950A (ru) Фармацевтический препарат и способ его приготовления
DK0436370T3 (da) Farmaceutisk præparat til kontrolleret afgivelse og fremgangsmåde til fremstilling deraf
ATE59289T1 (de) Verfahren zur herstellung einer darreichungsund dosierungsform fuer arzneimittel-wirkstoffe, reagentien oder andere wirkstoffe.
ATE246505T1 (de) Zubereitung enthaltend cefaclor oder cephalexin mit modifizierter freisetzungsmatrix
DE69133623D1 (de) Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung
KR860000865A (ko) 약제 제형의 제조방법
ATE211649T1 (de) Dosisform mit gesteuerter freigabe für kalium
PT916347E (pt) Solucoes farmaceuticas injectaveis contendo paracetamol e combinacoes de paracetamol com outras substancias activas
DE58903856D1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
KR880001302A (ko) 피복 가능한 이온 교환 수지
DE3856258D1 (de) Verfahren zur Herstellung eines Retardpräparates, das Diltiazem in einer einzigen Tagesdosis enthält
HUP9901208A2 (hu) (R)-5-Bróm-n-(1-etil-4-metil-hexahidro-1H-1,4-diazepin-6-il)-2-metoxi-6-(metil-amino)-3-piridin-karboxamid, eljárás előállítására és ezt a vegyületet tartalmazó gyógyászati készítmény

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application